Ecstasy counteracts catalepsy in rats, an anti-parkinsonian effect?
Werner J Schmidt, Andreas Mayerhofer, Anja Meyer, Karl-A Kovar
Neuroscience Letters September 27, 2002 DOI: 10.1016/s0304-3940(02)00823-6 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Preclinical animal study Peer reviewed |
|---|---|
| Population | Rats with haloperidol-induced parkinsonism |
| Intervention | 3 |
| Topics | MDMA |
| Key points | 3,4-Methylenedioxymethamphetamine ('Ecstasy') dose-dependently and potently reversed haloperidol-induced parkinsonism in rats. The authors argue that a supraadditive effect of the enantiomers indicates both enantiomers contribute to the antiparkinsonian effects at two different target sites. |
Abstract
Parkinson's disease is due to a dopamine deficiency caused by the degeneration of midbrain dopamine neurons. Current therapies are aimed to substitute dopamine or to directly stimulate postsynaptic dopamine receptors. However, not all patients profit from current therapies to the same extent, even serious side effects such as dyskinesias are complicating the therapy. Therefore, there is still a need for better anti-parkinsonian drugs. Here we show that some compounds from the 'Ecstasy'-derivatives exert potent anti-parkinsonian activity. 3,4-Methylenedioxymethamphetamine, 'Ecstasy' dose-dependently and very potently reversed haloperidol-induced parkinsonism in the rat. From the supraadditive effect of the enantiomers it may be concluded that both enantiomers contribute to the antiparkinsonian effects at two different target sites.
Comparable studies
Other preclinical and animal studies on MDMA, most cited first.
Citations in the library
Cited by 7
- MDMA and fenfluramine reduce L‐DOPA‐induced dyskinesia via indirect 5‐HT1A receptor stimulation European Journal of Neuroscience May 1, 2006
- The Neuropsychopharmacology and Toxicology of 3,4‐methylenedioxy‐N‐ethyl‐amphetamine (MDEA) CNS Drug Reviews June 1, 2004
- Early onset Parkinson's disease in the cycle of 3,4-methylenedioxymethamphetamine and substance use: a case report. Journal of Medical Case Reports September 23, 2023
- Is the Ecstasy-induced ipsilateral rotation in 6-hydroxydopamine unilaterally lesioned rats dopamine independent? Journal of Neural Transmission July 1, 2003
- Crystal Structure of a Fluoro Analogue of 3,4-(Methylenedioxy)amphetamine 2015
and 2 more in the library
Cites 7
- Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin Synapse 2000
- The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacological Reviews September 2003
- Enantio-selective cognitive and brain activation effects of N-ethyl-3,4-methylenedioxyamphetamine in humans. Neuropharmacology August 2001
- Enantioselektive Gewinnung und Kristallstruktur des Ecstasy-Analogons N-Ethyl-3,4-methylendioxyamphetamin-HCl (MDE) und seiner beiden Hauptmetaboliten MDA und HME / Enantioselective Production and Crystal Structure of the Ecstasy Analogue N-Ethyl-3,4- methylenedioxyamphetamine-HCl (MDE) and its Major Metabolites MDA and HME Zeitschrift für Naturforschung B December 1, 2000
- The effects of methylenedioxymethamphetamine (MDMA, "Ecstasy") on monoaminergic neurotransmission in the central nervous system. Progress in Neurobiology August 1996
and 2 more in the library